We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
- Authors
Relling, M V; Gardner, E E; Sandborn, W J; Schmiegelow, K; Pui, C-H; Yee, S W; Stein, C M; Carrillo, M; Evans, W E; Klein, T E; Clinical Pharmacogenetics Implementation Consortium
- Abstract
Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.
- Publication
Clinical pharmacology and therapeutics, 2011, Vol 89, Issue 3, p387
- ISSN
1532-6535
- Publication type
Journal Article
- DOI
10.1038/clpt.2010.320